SCHEMBL6319263

SCHEMBL6319263

CCOC(=O)c1c[nH]c2c(C)c(C=O)sc2c1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CLEC4M Q9H2X3 1/20 0.50
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM4E B2RXH2 4/20 0.45
MAPT P10636 2/20 0.44
KMT2A Q03164 4/20 0.43
GABRA1 P14867 3/20 0.43
GABRB2 P47870 3/20 0.43
MEN1 O00255 3/20 0.43
GABRB1 P18505 2/20 0.42
GABRA3 P34903 2/20 0.42
ALDH1A1 P00352 3/20 0.38
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479861 0.75 GABRA1 (0.51) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL6317607 0.74 BAZ2B (0.43) CYP1A2KDM4EMAPTKMT2AALDH1A1
SCHEMBL359436 0.74 CYP1A2 (0.56) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL10188399 0.71 GABRA1 (0.55) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL10474325 0.71 CLEC4M (0.51) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL1079651 0.69 KMT2A (0.50) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL14257469 0.69 GABRA1 (0.58) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL12325794 0.69 KDM4E (0.54) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL6480716 0.68 GABRA1 (0.52) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL12708943 0.68 CLEC4M (0.60) CLEC4MCYP1A2CYP3A4CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 CLEC4M 4191/4885CYP1A2 2676/4885CYP3A4 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.